NATR vs. VRCA, VSTM, CMRX, FBIO, HLF, USNA, NUS, MED, VERU, and EL
Should you be buying Nature's Sunshine Products stock or one of its competitors? The main competitors of Nature's Sunshine Products include Verrica Pharmaceuticals (VRCA), Verastem (VSTM), Chimerix (CMRX), Fortress Biotech (FBIO), Herbalife (HLF), USANA Health Sciences (USNA), Nu Skin Enterprises (NUS), Medifast (MED), Veru (VERU), and Estée Lauder Companies (EL).
Verrica Pharmaceuticals (NASDAQ:VRCA) and Nature's Sunshine Products (NASDAQ:NATR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, community ranking, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.
Nature's Sunshine Products has a net margin of 3.69% compared to Nature's Sunshine Products' net margin of -905.83%. Verrica Pharmaceuticals' return on equity of 10.59% beat Nature's Sunshine Products' return on equity.
In the previous week, Nature's Sunshine Products had 4 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 6 mentions for Nature's Sunshine Products and 2 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 1.24 beat Nature's Sunshine Products' score of 0.38 indicating that Nature's Sunshine Products is being referred to more favorably in the news media.
Nature's Sunshine Products has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.
42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.4% of Nature's Sunshine Products shares are owned by institutional investors. 42.6% of Verrica Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Nature's Sunshine Products shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Verrica Pharmaceuticals presently has a consensus target price of $13.50, indicating a potential upside of 58.64%. Nature's Sunshine Products has a consensus target price of $24.00, indicating a potential upside of 56.66%. Given Nature's Sunshine Products' higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Nature's Sunshine Products.
Verrica Pharmaceuticals has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Comparatively, Nature's Sunshine Products has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.
Verrica Pharmaceuticals received 2 more outperform votes than Nature's Sunshine Products when rated by MarketBeat users. Likewise, 64.94% of users gave Verrica Pharmaceuticals an outperform vote while only 62.89% of users gave Nature's Sunshine Products an outperform vote.
Summary
Nature's Sunshine Products beats Verrica Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Nature's Sunshine Products News Delivered to You Automatically
Sign up to receive the latest news and ratings for NATR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NATR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nature's Sunshine Products Competitors List
Related Companies and Tools
